These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
95 related articles for article (PubMed ID: 3840491)
1. Determination of N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenylamino]-4 -acridinecarboxamide in plasma by high-performance liquid chromatography. Jurlina JL; Paxton JW J Chromatogr; 1985 Aug; 342(2):431-5. PubMed ID: 3840491 [No Abstract] [Full Text] [Related]
2. Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide. Baguley BC; Denny WA; Atwell GJ; Finlay GJ; Rewcastle GW; Twigden SJ; Wilson WR Cancer Res; 1984 Aug; 44(8):3245-51. PubMed ID: 6547635 [TBL] [Abstract][Full Text] [Related]
3. The effect of food on the bioavailability and kinetics of the anticancer drug amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]-4 acridinecarboxamide in rabbits. Paxton JW J Pharm Pharmacol; 1986 Nov; 38(11):837-40. PubMed ID: 2879015 [TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacokinetics and protein binding of the anticancer drug, amsacrine and a new analogue, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino)phenyl-amino] -4-acridinecarboxamide in rabbits. Paxton JW; Jurlina JL Cancer Chemother Pharmacol; 1986; 16(3):253-6. PubMed ID: 3754493 [TBL] [Abstract][Full Text] [Related]
5. Dose-dependent pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methylsulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in rabbits. Paxton JW; Evans PC; Singh RM Cancer Chemother Pharmacol; 1987; 20(1):13-5. PubMed ID: 3621447 [TBL] [Abstract][Full Text] [Related]
6. The binding of amsacrine to human plasma proteins. Paxton JW; Jurlina JL; Foote SE J Pharm Pharmacol; 1986 Jun; 38(6):432-8. PubMed ID: 2873219 [TBL] [Abstract][Full Text] [Related]
7. Disposition of amsacrine and its analogue 9-([2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921) in plasma, liver, and Lewis lung tumors in mice. Kestell P; Paxton JW; Evans PC; Young D; Jurlina JL; Robertson IG; Baguley BC Cancer Res; 1990 Feb; 50(3):503-8. PubMed ID: 2297692 [TBL] [Abstract][Full Text] [Related]
8. Effects of a new amsacrine derivative, N-5-dimethyl-9-(2-methoxy-4-methylsulfonylamino)phenylamino-4- acridinecarboxamide, on cultured mammalian cells. Traganos F; Bueti C; Darzynkiewicz Z; Melamed MR Cancer Res; 1987 Jan; 47(2):424-32. PubMed ID: 2431770 [TBL] [Abstract][Full Text] [Related]
9. Development and validation of bioanalytical method for the determination of asulacrine in plasma by liquid chromatography. Ganta S; Paxton JW; Baguley BC; Garg S J Pharm Biomed Anal; 2008 Jan; 46(2):386-90. PubMed ID: 17981420 [TBL] [Abstract][Full Text] [Related]
10. The effect of cimetidine, phenobarbitone and buthionine sulphoximine on the disposition of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulphonylamino)phenylamino]- 4-acridinecarboxamide (CI-921) in the rabbit. Paxton JW; Evans PC; Hardy JR Cancer Chemother Pharmacol; 1989; 23(5):291-5. PubMed ID: 2706733 [TBL] [Abstract][Full Text] [Related]
11. Phase I trial of the amsacrine analogue 9-[( 2-methoxy-4-[(methylsulfonyl)amino]-phenyl]amino)-N,5-dimethyl-4- acridinecarboxamide (CI-921). Hardy JR; Harvey VJ; Paxton JW; Evans P; Smith S; Grove W; Grillo-Lopez AJ; Baguley BC Cancer Res; 1988 Nov; 48(22):6593-6. PubMed ID: 3180070 [TBL] [Abstract][Full Text] [Related]
12. The clinical pharmacokinetics of N-5-dimethyl-9-[(2-methoxy-4-methyl-sulfonylamino)phenylamino]-4 -acridinecarboxamide (CI-921) in a phase 1 trial. Paxton JW; Hardy JR; Evans PC; Harvey VJ; Baguley BC Cancer Chemother Pharmacol; 1988; 22(3):235-40. PubMed ID: 3409457 [TBL] [Abstract][Full Text] [Related]
13. Thiolytic cleavage and binding of the antitumour agent CI-921 in blood. Kestell P; Paxton JW; Robertson IG; Evans PC; Dormer RA; Baguley BC Drug Metabol Drug Interact; 1988; 6(3-4):327-36. PubMed ID: 3271644 [TBL] [Abstract][Full Text] [Related]
14. Analysis of the imidazoacridinone C1311 by high-performance liquid chromatography. Calabrese CR; Loadman PM J Chromatogr B Biomed Sci Appl; 1997 Mar; 690(1-2):275-81. PubMed ID: 9106053 [TBL] [Abstract][Full Text] [Related]
15. High-performance liquid-chromatographic method for the determination of 4'-(9-acridinylamino)methanesulfon-m-anisidide in plasma. Jurlina JL; Paxton JW J Chromatogr; 1983 Sep; 276(2):367-74. PubMed ID: 6688811 [TBL] [Abstract][Full Text] [Related]
17. Quantitation of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in plasma by high-performance liquid chromatography. Young D; Evans PC; Paxton JW J Chromatogr; 1990 Jun; 528(2):385-94. PubMed ID: 2384576 [TBL] [Abstract][Full Text] [Related]
18. Derivatives of amsacrine: determinants required for high activity against Lewis lung carcinoma. Baguley BC; Finlay GJ J Natl Cancer Inst; 1988 Apr; 80(3):195-9. PubMed ID: 3346911 [TBL] [Abstract][Full Text] [Related]
19. A comparison of the effects of aphidicolin and other inhibitors on topoisomerase II-directed cytotoxic drugs. Haldane A; Finlay GJ; Baguley BC Oncol Res; 1993; 5(3):133-8. PubMed ID: 8260750 [TBL] [Abstract][Full Text] [Related]
20. Determination of tacrine and its 1-hydroxy metabolite in plasma using column liquid chromatography with ultraviolet detection. Ekman L; Lindström B; Roxin P J Chromatogr; 1989 Sep; 494():397-402. PubMed ID: 2584339 [No Abstract] [Full Text] [Related] [Next] [New Search]